- Largest study to date analysing more than 40,000 COVID-19 cases confirmed by virus genome sequencing finds a two- fold increased risk of hospitalisation from delta versus alpha variant infections.
- Risk of emergency care visits or hospital admission was also 1.5 times higher for people infected with the delta variant compared to the alpha variant.
- Findings suggest that outbreaks of the delta variant are likely to lead to a greater burden on health services than the alpha variant, particularly in unvaccinated people and other vulnerable populations.
- Study findings primarily reflect the increased risk of hospitalisation among unvaccinated or partially vaccinated people, since these individuals made up the majority of cases in the study.
People infected with the SARS-CoV-2 delta variant have approximately double the risk of hospitalisation compared with those infected with the alpha variant, a study of more than 40,000 cases from England between 29 March and 23 May 2021, published in The Lancet Infectious Diseases journal has confirmed.
The risk of attending hospital for emergency care or being admitted to hospital within 14 days of infection with the delta variant was also one and a half times greater compared with the alpha variant (1.45-fold increase in risk).
This new study is the first to report hospitalisation risk for the delta versus alpha variants based on cases confirmed by whole-genome sequencing, which is the most accurate way to determine the virus variant.
Dr Gavin Dabrera, one of the study’s lead authors and a Consultant Epidemiologist at the National Infection Service, Public Health England, said: “This study confirms previous findings that people infected with Delta are significantly more likely to require hospitalisation than those with Alpha, although most cases included in the analysis were unvaccinated. We already know that vaccination offers excellent protection against Delta and as this variant accounts for over 98% of COVID-19 cases in the UK, it is vital that those who have not received two doses of vaccine do so as soon as possible. It is still important that if you have COVID-19 symptoms, stay home and get a PCR test as soon as possible.” [1]
The delta variant was first reported in India in December 2020 and early studies found it to be up to 50% more transmissible than the variant of COVID-19 that had previously gained dominance worldwide, known as the alpha variant, first identified in Kent, UK.
A preliminary study from Scotland previously reported a doubling in risk of hospitalisation with the delta variant compared with the alpha variant and it is suspected that delta is associated with more severe disease. The previous study used patients’ initial PCR test results and determined which variant they had by testing for a specific gene that is more common in the delta variant [2].
In the latest study, researchers analysed healthcare data from 43,338 positive COVID-19 cases in England between 29 March and 23 May 2021, including information on vaccination status, emergency care attendance, hospital admission, and other demographic characteristics. In all cases included in the study, samples of the virus taken from patients underwent whole genome sequencing to confirm which variant had caused the infection.
During the study period, there were 34,656 cases of the alpha variant (80%) and 8,682 cases of the delta variant (20%). While the proportion of delta cases in the study period overall was 20%, it grew to account for around two thirds of new COVID-19 cases in the week starting 17 May 2021 (65%, 3,973/6,090), indicating it had overtaken alpha to become the dominant variant in England.
Around one in 50 patients were admitted to hospital within 14 days of their first positive COVID-19 test (2.2% alpha cases, 764/34,656; 2.3% delta cases, 196/8,682). After accounting for factors that are known to affect susceptibility to severe illness from COVID-19, including age, ethnicity, and vaccination status, the researchers found the risk of being admitted to hospital was more than doubled with the delta variant compared with the alpha variant (2.26-fold increase in risk).
Multiple studies have shown that full vaccination prevents both symptomatic infection and hospitalisation, for both alpha and delta variants. Indeed, in this study, only 1.8% (794/43,338) of COVID-19 cases (with either variant) had received both doses of the vaccine; 74% of cases (32,078/43,338) were unvaccinated, and 24% (10,466/43,338) were partially vaccinated. The authors note it is therefore not possible to draw statistically significant conclusions about how the hospitalisation risk differs between vaccinated persons who later develop alpha and delta infections. The results from this study therefore primarily tell us about the risk of hospital admission for those who are unvaccinated or partially vaccinated.
Dr Anne Presanis, one of the study’s lead authors and Senior Statistician at the MRC Biostatistics Unit, University of Cambridge, said: "Our analysis highlights that in the absence of vaccination, any Delta outbreaks will impose a greater burden on healthcare than an Alpha epidemic. Getting fully vaccinated is crucial for reducing an individual’s risk of symptomatic infection with Delta in the first place, and, importantly, of reducing a Delta patient’s risk of severe illness and hospital admission.” [1]
The authors note several limitations to the study. Some demographic groups may be more likely to seek hospital care, which could have biased the results, and there may have been changes in hospital admission policy during the period of the study, although adjustment for demographics and calendar time should have minimised such bias. In addition, the authors did not have access to information about patients’ pre-existing health conditions, which are known to affect the risk of severe illness from COVID-19. They accounted for this indirectly using age, gender, ethnicity, and estimated level of socioeconomic deprivation.
NOTES TO EDITORS
The study was carried out by researchers from Public Health England and Cambridge University. It was funded by UK Research and Innovation, the Medical Research Council, the UK Government’s Department of Health and Social Care and the National Institute for Health Research.
[1] Quote direct from author and cannot be found in the text of the Article.
[2] A. Sheikh et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. The Lancet, 2021. DOI: 10.1016/S0140-6736(21)01358-1
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
For interviews with the Article author, please contact:
University of Cambridge Press Team
Tel: +44 7879 116949
Email: communications@admin.cam.ac.uk
NOTE: THE ABOVE LINK IS FOR JOURNALISTS ONLY; IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00475-8/fulltext
Contact The Lancet press office:
LONDON
Emily Head, Media Relations Manager
Tel: +44 (0) 7920 530997
emily.head@lancet.com
USA
Johanna Harvey, Media and Communications Manager, North America
Tel: +1 267-515-1767
johanna.harvey@lancet.com
OUTSIDE OF UK HOURS
Tel: +44 (0) 207 424 4249
Journal
The Lancet Infectious Diseases
Method of Research
Observational study
Subject of Research
People